Only one small biotech is on the calendar for the week ahead as the annual mid-February lull has been drawn out slightly longer than expected. That said, four deals are able to launch on Monday, and another three become eligible the week after, including high-profile deals Zscaler (Pending:ZS) (eligible Monday, March 5) and Dropbox (Pending:DBX) (eligible Monday, March 12).
U.S. IPO Calendar
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about!
Welcome to another edition of “3 Things In Biotech,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Organovo shows signs it can model....More>>>
In the week ahead, two recent IPO filers become eligible to launch roadshows, including tech unicorn AppDyanamics on Thursday. The provider of cloud-based enterprise software is a high profile name that could set the tone for venture-backed tech deals in 2017, testing investor appetite high-growth, large-loss businesses. Metallurgical coal producer Ramaco Resources can file IPO terms on Friday at....More>>>
Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.
The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>
The next shoe is set to drop in the high-flying immuno-oncology space, with genetically modified cell therapies close to becoming a reality. As these therapies are forecast to quickly become one of the fastest-growing segments of the $100 billion oncology market in the next few years, investors may want to consider taking a position in this emerging field before the first therapy reaches the market.
The decacorns keep coming. Spotify filed its highly-anticipated F-1, which sets it up for a public listing that could occur in late March.
Spotify is not an underwritten IPO. Its owners will simply be able to begin selling their shares on the NYSE. Yet, its $1 billion filing has plenty to analyze, and Renaissance will issue research to our institutional clients. Some quick....More>>>
“Decent people should ignore politics, if only they could be confident that politics would ignore them”
William F. Buckley Jr.
The biotech indices have gained more than seven percent in February. Small and mid-caps have been on the vanguard of the rally as M&A activity is off to a strong start in 2017. While I think the market overall is due for a “pause”,....More>>>
Analysis focus: Galectin
Today we will focus on Galectin Therapeutics (NASDAQ:GALT) after the company provided an update to investors and also released its financial results for 2017.
Galectin ended 2017 with $3.1 million in cash and cash equivalents on its balance sheet. The company had received $4.5 million in proceeds in January 2018 from common stock warrant exercises. In December....More>>>
With just one deal on the calendar for the week ahead, the annual February lull is coming to an end. After pushing back its IPO by a week, Latin America-focused SPAC Union Acquisition (LTN.U) aims to raise $100 million at a $125 million valuation.
U.S. IPO Calendar
Which biotechs have high prospects of being acquired in the near future? Many would place Incyte (NASDAQ:INCY) near the top of the list. The company’s oncology portfolio makes it an attractive target.But a target for whom?
Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), and Amgen (NASDAQ:AMGN) stand out as three of the most likely suitors for Incyte. Here’s why....More>>>